Penicillin V
Beta-Lactamase Sensitive Penicillins
- Drug class
- Beta-Lactamase Sensitive Penicillins
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 5
Overview
Penicillin V is an active pharmaceutical ingredient in the Beta-Lactamase Sensitive Penicillins group (J01CE). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 3 | October 15, 2025 |
| GB United Kingdom | MHRA | 2 | July 25, 2025 |
USUnited States· FDA
3 products
Uses
INDICATIONS AND USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response.
NOTE:
GBUnited Kingdom· MHRA
2 products
Uses
Phenoxymethylpenicillin and potassium phenoxymethylpenicillin are indicated in the treatment of mild to moderately severe infections associated with micro-organisms whose susceptibility to penicillin is within the range of serum levels attained with these dosage forms.
The following infections will usually respond to adequate doses:
Streptococcal infections (without bacteraemia): Mild to moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas.
Pneumococcal infections:
Mild to moderately severe infections of the respiratory tract.
Staphylococcal infections sensitive to penicillin:
Mild infections of the skin and soft tissues.
Fusospirochaetosis (Vincent’s gingivitis and pharyngitis):
Sources & citations
- [1]FDA DailyMed · 0151c742-7525-47… · revised October 15, 2025 [PDF]
- [2]MHRA (UK) · PL204160132 · revised July 25, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.